Dr. Weiss on Immunotherapy Combinations in Head and Neck Cancer

Video

In Partnership With:

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.

In addition to the approved PD-1 agents, PD-L1 agents will soon be used in the recurrent metastatic setting, says Weiss. Data with combinations of CTLA-4 agents such as ipilimumab (Yervoy) and nivolumab (Opdivo) or durvalumab (Imfinzi) and tremelimumab will be reported in the coming months, as well.

The combination of PD-1 and IDO inhibitors is also showing promise, Weiss says.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD